Sign up USA
Proactive Investors - Run By Investors For Investors
Market: NASDAQ
52-week High/Low: $152.71 / $47.00
Sector: Pharmaceuticals
Market Cap: $14,636.60M
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection.

Alnylam Pharmaceuticals

Interactive graph

col 3
col 4
col 5
col 6

Alnylam Pharmaceuticals Timeline

Market Reports Including ALNY

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use